Protocol for a Multi-Center Confirmatory Trial to Evaluate the Differential Diagnostic Performance of Contrast-Enhanced Ultrasonography Using Perflubutane in Patients with a Pancreatic Mass: A Multicenter Prospective Study

Yasunobu Yamashita,Toshio Shimokawa,Reiko Ashida,Yoshiki Hirooka,Takuji Iwashita,Hironari Kato,Toshifumi Kin,Atsushi Masamune,Haruo Miwa,Eizaburo Ohno,Hideyuki Shiomi,Atsushi Sofuni,Mamoru Takenaka,Masayuki Kitano

DOI: https://doi.org/10.3390/diagnostics14020130

IF: 3.6

2024-01-06

Diagnostics

Abstract:For pancreatic masses, an evaluation of their vascularity using contrast-enhanced ultrasonography can help improve their characterization. This study was designed to evaluate the utility and safety of contrast-enhanced transabdominal ultrasonography (CE-TUS) and endoscopic ultrasonography (CE-EUS) in the diagnosis of pancreatic masses including solid or cystic masses. This multi-center comparative open-label superiority study is designed to compare Plain (P)-TUS/EUS alone with P-TUS/P-EUS plus CE-TUS/CE-EUS. Three hundred and one patients with a total of 232 solid pancreatic masses and 69 cystic masses were prospectively enrolled. The primary endpoints are to compare the diagnostic accuracy between P-TUS/P-EUS alone and P-TUS/P-EUS plus CE-TUS/CE-EUS for both the TUS and EUS of solid pancreatic masses, and to compare the diagnostic accuracy between P-EUS alone and P-EUS plus CE-EUS in cystic pancreatic masses. The secondary endpoints are to compare the diagnostic sensitivity and specificity of P-TUS/P-EUS alone and P-TUS/P-EUS plus CE-TUS/CE-EUS for pancreatic solid/cystic masses, and the accuracy of P-TUS alone and P-TUS plus CE-TUS for pancreatic cystic masses. Other secondary endpoints included comparing the diagnostic sensitivity, specificity, and accuracy of CE-TUS, CE-EUS and CE-computed tomography (CT) for solid/cystic pancreatic masses. The safety, degree of effective enhancement, and diagnostic confidence obtained with CE-TUS/CE-EUS will also be assessed.

medicine, general & internal

What problem does this paper attempt to address?

The main purpose of this paper is to design a multicenter confirmatory trial to evaluate the differential diagnostic performance and safety of using perflubutane as a contrast agent in contrast-enhanced abdominal ultrasound (CE-TUS) and contrast-enhanced endoscopic ultrasound (CE-EUS) for diagnosing pancreatic masses (including solid and cystic masses).

Specifically, the objectives of the study are:
1. **Compare diagnostic accuracy**: The primary endpoint is to compare the diagnostic accuracy of using only conventional ultrasound (P-TUS/P-EUS) versus using combined contrast-enhanced ultrasound (P-TUS/P-EUS plus CE-TUS/CE-EUS) in diagnosing solid pancreatic masses; and in diagnosing cystic pancreatic masses, using only conventional endoscopic ultrasound (P-EUS) versus using combined contrast-enhanced endoscopic ultrasound (P-EUS plus CE-EUS).
2. **Compare sensitivity, specificity, and accuracy**: Secondary endpoints include comparing the sensitivity, specificity, and accuracy of using only conventional ultrasound versus combined contrast-enhanced ultrasound in diagnosing solid and cystic pancreatic masses; and in diagnosing cystic pancreatic masses, using only conventional abdominal ultrasound versus combined contrast-enhanced abdominal ultrasound.
3. **Other comparisons**: Also included are comparisons of the sensitivity, specificity, and accuracy of contrast-enhanced abdominal ultrasound, contrast-enhanced endoscopic ultrasound, and contrast-enhanced computed tomography (CE-CT) in diagnosing solid and cystic pancreatic masses.
4. **Evaluate safety and enhancement effect**: Additionally, the study will evaluate the safety of using contrast-enhanced ultrasound, the degree of effective enhancement, and the diagnostic confidence obtained.

The study plans to achieve these objectives by prospectively collecting data on patients' medical history, physical examination results, laboratory data, pathology, clinical information, and adverse events. Furthermore, it details the standard settings for image acquisition, methods for determining the final diagnosis, data monitoring and auditing procedures, statistical analysis processes, and sample size calculation methods. The study aims to verify whether the use of contrast-enhanced ultrasound technology can improve the diagnostic accuracy of pancreatic masses and provide guidance for clinical practice.